Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy

Post time 2022-1-24 01:47:41

journal：JAMA Dermatology

Authors：Kimberly Tang; Jayhyun Seo; Bruce C. Tiu; Thomas K. Le; Vartan Pahalyants; Neel S. Raval; Pearl O. Ugwu-Dike; Leyre Zubiri; Vivek Naranbhai; Mary Carrington; Alexander Gusev; Kerry L. Reynolds; Nicole R. LeBoeuf; Maryam M. Asgari; Shawn G. Kwatra; Yevgeniy R. Semenov

Published date：--

DOI：10.1001/jamadermatol.2021.5476

Article link：http://dx.doi.org/10.1001/jamadermatol.2021.5476

Article Source：American Medical Association (AMA)。

Remark：

Post time 2022-1-24 01:47:42

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2022-1-24 03:39:35

: This post has been completed
Completed attachments will be deleted within 24 hours.

[JAMA] Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[JAMA] Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy Copy